Payment overview · 2025
General Payments
$822.57
20 reported records · 13 companies
Healthcare provider profile · identity verified
Racheed M Atassi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROMEO, MI · NPI 1710969639
Verified facts
What the public records show
CMS Open Payments records show Racheed M Atassi, M.D. received $822.57 in general payments during 2025 across 20 reported records.
Corcept Therapeutics accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $178.11 | 21.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.68 | 19.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $126.84 | 15.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.74 | 15.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.51 | 4.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.59 | 4.7% | 2 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $28.16 | 3.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.88 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.49 | 2.9% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.61 | 2.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.80 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.43 | 2.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.73 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $822.57 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $178.11 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $156.68 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $126.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 75 |
| Losartan Potassium | Losartan Potassium | 193 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 69 |
| Lisinopril | Lisinopril | 156 | 49 |
| Omeprazole | Omeprazole | 145 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 51 |
| Eliquis | Apixaban | 124 | 49 |
| Furosemide | Furosemide | 123 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 86 |
| Metformin Hcl | Metformin Hcl | 115 | 35 |
| Simvastatin | Simvastatin | 115 | 29 |
| Prednisone | Prednisone | 112 | 90 |
| Alprazolam | Alprazolam | 99 | 30 |
| Ozempic | Semaglutide | 83 | 18 |
| Carvedilol | Carvedilol | 79 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 47 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 55 |
| Januvia | Sitagliptin Phosphate | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 33 |
| Meloxicam | Meloxicam | 64 | 14 |
| Gabapentin | Gabapentin | 62 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | 16 |
| Clonidine Hcl | Clonidine Hcl | 51 | 14 |
| Jardiance | Empagliflozin | 50 | 23 |
| Sertraline Hcl | Sertraline Hcl | 50 | 17 |
| Ibuprofen | Ibuprofen | 48 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 19 |
| Cephalexin | Cephalexin | 43 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Azithromycin | Azithromycin | 36 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 17 |
| Tramadol Hcl | Tramadol Hcl | 36 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 21 |
| Atenolol | Atenolol | 32 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 11 |
| Allopurinol | Allopurinol | 31 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 28 |
| Meclizine Hcl | Meclizine Hcl | 31 | 21 |
| Diazepam | Diazepam | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 20 |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Famotidine | Famotidine | 26 | 11 |
| Nifedipine Er | Nifedipine | 26 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | 11 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 13 |
| Entresto | Sacubitril/Valsartan | 24 | 11 |
| Finasteride | Finasteride | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Sucralfate | Sucralfate | 23 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | 12 |
| Clonidine | Clonidine | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 16 |
| Glipizide | Glipizide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $822.57 · 20 records | Corcept Therapeutics | ACCRUFER, AIRSUPRA, DANZITEN, ELIQUIS, GIVLAARI, Kerendia, Korlym, NURTEC ODT, OJJAARA, REXULTI, TRELEGY ELLIPTA, TZIELD, Wegovy, ZEPBOUND, iTIND System | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error